CoChat
Sign Up
Cited by 7Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesPharmacology and Obesity Treatment

Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial

Gerwe, Martin, Stollhoff, Kirsten, Mossakowski, Jacek, Kuehle, Hans-Juergen, Goertz, Ulrich, Schaefer, Christopher, Bogdanow, Manuela, Heger, Steffen·2009·ADHD Attention Deficit and Hyperactivity Disorders
DOI 10.1007/s12402-009-0010-6
Open this paper in CoChat — free account

Abstract

Attention-deficit/hyperactivity disorder may have substantial impact on family life, peer interactions, and quality of life. Stimulants are recommended as first-line pharmacotherapy for ADHD. OROS(®) MPH (Concerta(®)) is a long-acting preparation with duration of effect for up to 12 h. In this 8-week, prospective, open-label, non-interventional trial the impact of therapy with OROS(®) MPH on functioning in four different areas of life (school, recreation, family life, and peer interaction), severity of disease, and quality of life (QoL) as well as tolerability were investigated under daily routine care. 306 patients, aged 10.2±2.3 years, were either transitioned to OROS(®) MPH from short-acting, immediate-release MPH (-IR) preparations (n=231; 75%), or treatment was initiated with OROS(®) MPH in MPH-naïve patients (n =75; 25%). In both groups, therapy with OROS(®) MPH was associated with significant improvements in daily functioning, severity of disease, and QoL. Adverse events (AE) were documented in 160 patients (52.3%). In 95 patients (31.0%) a causal relationship was assessed as at least possible. Four serious AEs were reported in 2 patients and rated as doubtfully related to study medication. Most frequent AEs (≥5% of patients) were insomnia, anorexia, ineffectiveness of medication, and headache. In 12.1% of patients AE led to discontinuation of study participation. Considering the limitations of this non-interventional study, the results refer to the importance of a the…

Integrity signals

Registry

Crossref · 10.1007/s12402-009-0010-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The broad improvements in participant-perceived QOL observed in this trial are in line with those previously described with psychostimulant and nonstimulant treatment in children, adolescents, and adults with ADHD.

    “The broad improvements in participant-perceived QOL observed currently are in line with those described previously with psychostimulant and nonstimulant treatment in children, adolescents, and adults with ADHD (Spencer et al. 2008; Cannon et al. 2009; Gerwe et al. 2009; Brown and Landgraf 2010; Wehmeier et al. 2010; Berek et al. 2011; Brams et al. 2011).”

    From Participant-Perceived Quality of Life in a Long-Term, Open-Label Trial of Lisdexamfetamine Dimesylate in Adolescents with Attention-Deficit/Hyperactivity Disorder (2014) · cites this paper as Gerwe et al. 2009

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gerwe, M., Stollhoff, K., Mossakowski, J., Kuehle, H.-J., Goertz, U., Schaefer, C., Bogdanow, M., & Heger, S.
Affiliations
  • Johnson & Johnson (Germany) (DE)
  • ClinAssess (Germany) (DE)
Corresponding author
Gerwe, Martin
Venue
ADHD Attention Deficit and Hyperactivity Disorders
Publisher
Springer Science and Business Media LLC
Published
2009-08-06
Volume
1
Issue
2
Pages
175-186
ISSN
  • 1866-6116 (ISSN-L)
  • 1866-6647
DOI
10.1007/s12402-009-0010-6
OpenAlex
W2063445955
Cited by
7
References
5
Citations by year
2018: 1 · 2016: 1 · 2015: 2 · 2014: 3
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • ADHD Attention Deficit and Hyperactivity Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
attention deficit hyperactivity disorder, OROS methylphenidate, Concerta, long-acting stimulants, quality of life, daily functioning, disease severity, tolerability, adverse events, children and adolescents, peer interaction, academic performance
MeSH terms
Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Delayed-Action Preparations, Family, Female, Humans, Male, Methylphenidate, Peer Group, Quality of Life, Social Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review